Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 6
2005 5
2006 5
2007 3
2008 6
2009 13
2010 9
2011 12
2012 12
2013 22
2014 11
2015 21
2016 18
2017 13
2018 7
2019 11
2020 10
Text availability
Article attribute
Article type
Publication date

Search Results

174 results
Results by year
Filters applied: . Clear all
Page 1
Respiratory syncytial virus: prospects for new and emerging therapeutics.
Jorquera PA, Tripp RA. Jorquera PA, et al. Among authors: tripp ra. Expert Rev Respir Med. 2017 Aug;11(8):609-615. doi: 10.1080/17476348.2017.1338567. Epub 2017 Jun 14. Expert Rev Respir Med. 2017. PMID: 28574729 Review.
Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.
Hijano DR, Vu LD, Kauvar LM, Tripp RA, Polack FP, Cormier SA. Hijano DR, et al. Among authors: tripp ra. Front Immunol. 2019 Mar 26;10:566. doi: 10.3389/fimmu.2019.00566. eCollection 2019. Front Immunol. 2019. PMID: 30972063 Free PMC article. Review.
Gene-edited vero cells as rotavirus vaccine substrates.
Orr-Burks N, Murray J, Wu W, Kirkwood CD, Todd KV, Jones L, Bakre A, Wang H, Jiang B, Tripp RA. Orr-Burks N, et al. Among authors: tripp ra. Vaccine X. 2019 Oct 8;3:100045. doi: 10.1016/j.jvacx.2019.100045. eCollection 2019 Dec 10. Vaccine X. 2019. PMID: 31660537 Free PMC article.
A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo.
Bar-Peled Y, Diaz D, Pena-Briseno A, Murray J, Huang J, Tripp RA, Mousa JJ. Bar-Peled Y, et al. Among authors: tripp ra. J Virol. 2019 Sep 12;93(19):e00342-19. doi: 10.1128/JVI.00342-19. Print 2019 Oct 1. J Virol. 2019. PMID: 31292250 Free PMC article.
Development of a Zika vaccine.
Tripp RA, Ross TM. Tripp RA, et al. Expert Rev Vaccines. 2016 Sep;15(9):1083-5. doi: 10.1080/14760584.2016.1192474. Epub 2016 Jun 6. Expert Rev Vaccines. 2016. PMID: 27212079 Review. No abstract available.
Original Antigenic Sin and Respiratory Syncytial Virus Vaccines.
Tripp RA, Power UF. Tripp RA, et al. Vaccines (Basel). 2019 Sep 6;7(3):107. doi: 10.3390/vaccines7030107. Vaccines (Basel). 2019. PMID: 31500131 Free PMC article.
Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro.
Jorquera PA, Mathew C, Pickens J, Williams C, Luczo JM, Tamir S, Ghildyal R, Tripp RA. Jorquera PA, et al. Among authors: tripp ra. J Virol. 2019 Feb 5;93(4):e01684-18. doi: 10.1128/JVI.01684-18. Print 2019 Feb 15. J Virol. 2019. PMID: 30541831 Free PMC article.
Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.
Caidi H, Miao C, Thornburg NJ, Tripp RA, Anderson LJ, Haynes LM. Caidi H, et al. Among authors: tripp ra. Antiviral Res. 2018 Jun;154:149-157. doi: 10.1016/j.antiviral.2018.04.014. Epub 2018 Apr 17. Antiviral Res. 2018. PMID: 29678551
174 results
Jump to page
Feedback